Anti-idiotype cancer vaccine 105AD7

Drug Profile

Anti-idiotype cancer vaccine 105AD7

Alternative Names: 105AD7; Onyvax-105

Latest Information Update: 05 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Nottingham
  • Developer Cancer Research Technology; National Cancer Institute (USA); Onyvax
  • Class Cancer vaccines; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Colorectal cancer; Prostate cancer; Sarcoma

Most Recent Events

  • 31 May 2007 A second-generation version of Onyvax 105 is being developed, which will enter preclinical development
  • 05 Mar 2004 Phase-I clinical trials in Sarcoma in United Kingdom (Parenteral)
  • 02 Jun 2000 Onyvax has been awarded a US patent covering 105AD7
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top